Clinical Trials · NCT06649045
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 712
- Start date
- Oct 2024
- Locations
- 66 sites, 9 countries
- Primary endpoint
- Change from Baseline in Apnea-Hypopnea Index (AHI)